Relay Therapeutics, Inc. (NASDAQ: RLAY)

Relay Therapeutics, Inc. (RLAY) is a clinical-stage precision medicine company that operates in the biotechnology sector of the healthcare industry. The company's primary business activities involve the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and genetic diseases. Relay Therapeutics generates revenue through the development and commercialization of its product candidates, including RLY-2608, lirafugratinib (RLY-4008), and migoprotafib (GDC-1971, formerly known as RLY-1971).

RLY-2608 is the company's lead product candidate, which is a mutant-selective inhibitor of PI3Kα, a protein that is frequently mutated in cancer. The company has completed a Phase 1 clinical trial of RLY-2608 and is currently conducting a Phase 2 clinical trial in patients with HR+, HER2- breast cancer. Lirafugratinib (RLY-4008) is a potent, selective, and oral small molecule inhibitor of FGFR2, which is a protein that is frequently mutated in cancer. The company has completed a Phase 1 clinical trial of lirafugratinib and is currently conducting a Phase 2 clinical trial in patients with FGFR2-altered tumors. Migoprotafib (GDC-1971, formerly known as RLY-1971) is a product candidate that is being developed in collaboration with Genentech, Inc. It is a small molecule inhibitor of SHP2, which is a protein that is involved in various cellular processes, including cell growth and differentiation.

Relay Therapeutics has a strong competitive advantage in the development of its product candidates due to its proprietary platform, which combines experimental and computational capabilities to identify and validate novel targets and develop selective inhibitors. The company's platform has been used to develop multiple product candidates, including RLY-2608, lirafugratinib, and migoprotafib. The company faces competition from other companies that are developing similar product candidates; however, it believes that its proprietary platform and expertise in computational biology and medicinal chemistry give it a competitive advantage in the development of its product candidates.

The company's customers include D.E. Shaw Research, Genentech, and other biotechnology and pharmaceutical companies. Relay Therapeutics has collaborations with these companies to develop and commercialize its product candidates. As of December 31, 2023, Relay Therapeutics co-owned with D.E. Shaw Research pending U.S. and foreign patent applications covering its lead PI3K program, which are directed to the composition of matter for the drug candidates of the program, including RLY-2608, analogs thereof, as well as methods of making and using these compounds. Any U.S. or foreign patents that may issue from this patent family, if granted and all appropriate maintenance fees paid, would be scheduled to expire in 2041, excluding any additional term for patent term adjustment or patent term extension, if applicable.